Why carry out this study?

This study was performed to assess the safety, tolerability, and duration of therapeutic responses of repeated rimabotulinimtoxinB (RIMA) injections in adults with troublesome sialorrhea as required for US regulatory approval

What was learned from the study?

Repeated treatment with RIMA for sialorrhea was safe and well-tolerated through 1 year of treatment

Treatment with RIMA was consistently effective at reducing unstimulated salivary flow rate over repeated treatment cycles

Although the effects of RIMA were observed to wear off, most clinical measures were maintained significantly below pre-treatment baseline values across treatment cycles (mean injection interval 13.4 weeks)